Cymfony's Influence 2.0

Great video -- The Advertiser/Consumer Breakup

Tired of all the conference blah-blah about how marketing must change? Are you still meeting resistance in your organizations to what you know has to be done to adapt to consumer attitude and behavior changes. Maybe you should circulate this video.

Here is a hilarious video that IMHO perfectly captures the state of marketing today. Kudos to Microsoft Digital Advertising Solutions for putting it together.

The Break Up
Uploaded by geertdesager

New White Paper Addresses Regulatory Issues in Social Media for Pharma Marketers

I'm pleased to announce the newest Cymfony Influence 2.0 White Paper: "Connecting with Patients, Overcoming Uncertainty". We've collaborated with other industry experts to help pharmaceutical companies navigate the complexities of launching social media initiatives within the restrictions of DTC promotion regulations.

We're often asked by our pharma clients and prospects how to engage in social media given the strict FDA regulations around direct-to-consumer marketing. The FDA hasn't issued any guidance (in fact, they haven't issued guidance for Internet marketing). For a long time we looked for others who had made suggestions or analyzed the issues involved, to no avail.

So we've put a stake in the ground -- you can download the paper here. I had two great co-authors on this project: John Serio, a lawyer with Seyfarth Shaw LLP who specializes in food and drug law and regulations, and Fard Johnmar of Envision Solutions, a healthcare marketing communications consultant.

In the paper, we propose a framework for identifying the key issues across the entire spectrum of social media types. We review the core principles that are the foundation of DTC promotion regulation and discuss how they should be viewed in light of social media's unique characteristics. We zero in to show how to assess adverse event reporting requirements, off-label promotion risks, and fair balance when designing a social media initiative.    

Of course, nothing substitues for detailed FDA guidance. But we believe drug companies can participate in many types of social media without undue risk. We hope this paper will give marketers, regulatory compliance, and legal professionals in healthcare companies a common understanding of the issues, and ideas on how to mitigate the risks and become part of the active conversation that patients are having every day. 

My co-authors and I will also present these ideas in a webinar on September 11 at 1:00 eastern time. I hope you will register and join us on the call.

To the best of my knowledge, this is the first paper of its kind. I hope it will stimulate a lot of discussion and that you'll share your thoughts with me here.